Mezzion Pharmaceuticals' publication of the FUEL FALD study advances clinical evidence for udenafil in Fontan-associated liver disease, potentially boosting its pediatric cardiology pipeline
Executive summary: Mezzion Pharmaceuticals announced the peer‑reviewed publication of the FUEL FALD study in Pediatric Cardiology, detailing outcomes of udenafil in Fontan circulation patients. The study provides clinical evidence that could support future development of udenafil as a treatment for Fontan‑associated liver disease, potentially impacting Mezzion’s pipeline and investor outlook.
Who is involved: Mezzion Pharmaceuticals, the study investigators, and the journal Pediatric Cardiology.
Likely next: Further clinical trials, potential pursuit of orphan drug designation, and regulatory discussions regarding udenafil for FALD.
On July 16, 2026, Mezzion Pharmaceuticals announced that its FUEL FALD study was peer‑reviewed and published in Pediatric Cardiology. The study evaluates the use of udenafil in patients with Fontan circulation and reports findings that support further investigation of the drug for Fontan‑associated liver disease. The publication adds to the growing body of evidence surrounding udenafil’s role in this patient population. No regulatory approval or commercial launch was announced alongside the study.
Timeline
- — FUEL FALD Study Published in Pediatric Cardiology (PR Newswire)
Analysis — what this means
Sectors affected
- Pediatric cardiology therapeutics
- Fontan‑associated liver disease treatment
Historical parallels
- Sildenafil studied in Fontan circulation patients, published 2018
Key entities
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped